Zhengye Biotechnology Holding Ltd(ZYBT) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 25 at 7:30 PM ET (Korea 9/26 08:30)
Full metrics table
| Index | - | P/E | - | EPS (ttm) | -0.21 | Insider Own | 74.09% | Shs Outstand | 29.7M | Perf Week | -4.74% |
| Market Cap | 0.04B | Forward P/E | - | EPS next Y | - | Insider Trans | - | Shs Float | 7.7M | Perf Month | -28.69% |
| Enterprise Value | 0.05B | PEG | - | EPS next Q | - | Inst Own | 0.34% | Short Float | 1.78% | Perf Quarter | 82.93% |
| Income | -0.01B | P/S | 2.4 | EPS this Y | - | Inst Trans | -7.08% | Short Ratio | 0.03 | Perf Half Y | 54.33% |
| Sales | 0.02B | P/B | 1.73 | EPS next 5Y | - | ROA | -14.98% | Short Interest | 0.14M | Perf YTD | 13.48% |
| Book/sh | 0.75 | P/C | 5.22 | EPS past 3/5Y | - | ROE | -26.09% | 52W High | -83.71% ($8.01) | Perf Year | -56.5% |
| Cash/sh | 0.25 | P/FCF | 22.42 | Sales past 3/5Y | -25.18% -16.43% | ROIC | -26.28% | 52W Low | 112.02% ($0.62) | Perf 3Y | - |
| Dividend Est. | - | EV/EBITDA | - | EPS Y/Y TTM | -717.42% | Gross Margin | 20.41% | Volatility(W/M) | 6.14% 5.91% | Perf 5Y | - |
| Dividend TTM | - | EV/Sales | 3.11 | Sales Y/Y TTM | -37.53% | Oper. Margin | -60.73% | ATR (14) | 0.16 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 0.8 | EPS Q/Q | -2195.59% | Profit Margin | -60.22% | RSI (14) | 41.38 | Recom | - |
| Dividend Gr. 3/5Y | - | Current Ratio | 1.14 | Sales Q/Q | -40.44% | SMA20 | -12.4% ($1.48) | Beta | -2.41 | Target Price | - |
| Payout | - | Debt/Eq | 0.3 | Earnings | - | SMA50 | -24.39% ($1.72) | Rel Volume | 0 | Prev Close | $1.31 |
| Employees | 269 | LT Debt/Eq | 0.04 | EPS/Sales Surpr. | - | SMA200 | 11.26% ($1.17) | Avg Volume(3M) | 5.12M | Price | $1.3 |
| IPO | 2025/1/7 | Option/Short | No/Yes | Trades | 118 | Volume | 19,358 | Change | -0.38% |
🐷 Zheng Yi Biotechnology () is a company that researches, develops, manufactures, and sells veterinary vaccines for livestock and companion animals in China. It holds a vaccine portfolio targeting pigs, cattle, sheep, poultry, dogs, and cats, and is expanding into the companion animal vaccine market.
Over the past 1 year, on the lower side
84% below its 1-year high.
Traded less than usual That is 0% of its average volume.
ZYBT has weak earning power
Of every $100 in sales, $60.73 is lost.
Tap to view numbers
Relative to sales, the price is about the industry average
Loss-making, so we compare on sales. For a company selling $100 a year, you would pay $240. Peers typically go for $219.
Tap to view numbers
Holding long would have lost money
Tap to view numbers
No dividend
There is no profit to distribute yet.
Institutions barely hold it
Institutions hold 0.3%.
Tap to view numbers
It ranks #64 of 83 in the industry
Based on market cap of $39M.
SCYX#62 Scynexis Inc $44M PER - 
IXHL#63 Incannex Healthcare Inc $40M PER - ZYBT#64 Zhengye Biotechnology Holding Ltd $39M PER - 
RMTI#65 Rockwell Medical Inc $34M PER - 
CPHI#66 China Pharma Holdings Inc $32M PER - 
FAQ
What kind of company is ZYBT?
ZYBT belongs to the Healthcare sector and operates in the Drug Manufacturers - Specialty & Generic industry.
What is the market cap of ZYBT?
The market cap of ZYBT is approximately $39M, ranking 5,051 within its sector.
What is the 52-week high and low for ZYBT?
ZYBT has recorded a 52-week high of $8.01 and a low of $0.62.
